JHL Biotech to Provide Manufacturing Services to BeiGene for Immuno-oncology Program13 Jun 2016
WUHAN, China, June 13, 2016—JHL Biotech, Inc. (TWSE: 6540) (“JHL”) announces that it has entered into a contract manufacturing agreement with BeiGene, Ltd. (NASDAQ: BGNE) (“BeiGene”) for development and IND-enabling production of a new biologic in BeiGene’s immuno-oncology pipeline. This marks the third collaboration between the two companies, with JHL providing services to BeiGene for the development and manufacturing of certain early stage pipeline programs.
We aim to make Biopharmaceuticals more Affordable10 Jun 2016
Led by an experienced team of Genentech and Amgen veterans JHL Biotech aims to make biopharmaceuticals affordable and accessible to all patients through manufacturing innovation Several Asian companies have been increasing their focus on biosimilars, terming it a long term prospect. Although currently small and focused on few diseases, the biosimilars opportunity is all set to grow, thanks to the unprecedented patent cliff and rising healthcare costs. Biosimilars are an affordable option for Asia's growing healthcare needs and this has offered a clear potential for players in emerging Asian countries to set up operations and leverage this lucrative opportunity.
KUBio Coverage10 May 2016
News Coverage on JHL Wuhan KUBio.